NFKB1 and glioblastoma: The proliferation results indicated that the EZH2 inhibitor EPZ-6438 synergised with the NF-κb inhibitor CAPE in inducing anti-proliferative activities in both LN229 and U251 glioblastoma cell lines (Fig. 7g and Fig. S7a, b).